TY - JOUR
T1 - Osimertinib vs. erlotinib combined with an angiogenesis inhibitor in EGFR-mutated non-small cell lung cancer with malignant pleural effusion
T2 - a retrospective cohort study
AU - Hata, Tae
AU - Yamada, Tadaaki
AU - Mikami, Koji
AU - Yokoyama, Toshihide
AU - Oba, Tomohiro
AU - Goto, Yasuhiro
AU - Furuya, Naoki
AU - Futamura, Shun
AU - Taniguchi, Hirokazu
AU - Okimoto, Tamio
AU - Hirai, Soichi
AU - Uda, Sayaka
AU - Okada, Asuka
AU - Watanabe, Rie
AU - Ishizaki, Naoko
AU - Kawachi, Hayato
AU - Kijima, Takashi
AU - Takayama, Koichi
N1 - Publisher Copyright:
© AME Publishing Company. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
PY - 2026/8/31
Y1 - 2026/8/31
N2 - Background: Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. Erlotinib plus an angiogenesis inhibitor (erlotinib+A) has demonstrated efficacy in controlling malignant pleural effusion (MPE) through reduction of vascular permeability; however, no clinical trials have directly compared its MPE control efficacy with that of osimertinib. This study aimed to compare the efficacy of osimertinib vs. erlotinib+A in controlling MPE in patients with EGFR-mutant NSCLC. Methods: This multicenter retrospective cohort study analyzed longitudinal medical records of patients with advanced or recurrent EGFR-mutant NSCLC presenting with MPE at treatment initiation who received osimertinib or erlotinib+A at 14 institutions in Japan between November 2009 and October 2023. Patients with squamous cell carcinoma were excluded. The primary endpoint was time to MPE recurrence [MPE-progression-free survival (PFS)]. Secondary endpoints included PFS, overall survival (OS), and adverse events (AEs) graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Multivariable Cox proportional hazards regression served as the primary analysis, with propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) utilized for sensitivity analyses. Results: Among 421 patients (median age, 73 years; 65% female; 66% never-smokers; 99% adenocarcinoma), 373 received osimertinib and 48 received erlotinib+A. In the multivariable Cox regression analysis, no significant differences were observed between the osimertinib and erlotinib+A groups in MPE-PFS [adjusted hazard ratio (HR): 0.79; 95% confidence interval (CI): 0.54–1.15; P=0.22], PFS (adjusted HR: 0.87; 95% CI: 0.60–1.25; P=0.45), or OS (adjusted HR: 0.95; 95% CI: 0.63–1.44; P=0.83). However, a significant interaction between the treatment regimen and EGFR mutation type was identified (P=0.004 for MPE-PFS). Subgroup analysis demonstrated that osimertinib was significantly superior to erlotinib+A in patients with EGFR exon 19 deletions (MPE-PFS: adjusted HR: 0.38; 95% CI: 0.21–0.67; P<0.001), whereas no difference was observed in those with L858R mutations. Grade ≥3 AEs were more frequent in the erlotinib+A group (38% vs. 21%, P=0.02), whereas osimertinib was associated with a higher incidence of all-grade interstitial pneumonia (21% vs. 6%, P=0.01). Conclusions: Osimertinib showed comparable efficacy to erlotinib+A in MPE control with a more favorable safety profile. Subgroup analysis suggested a particular benefit in patients harboring EGFR exon 19 deletions, highlighting the potential importance of mutation subtype-based treatment selection. Given the retrospective design and potential for residual confounding, prospective validation is warranted.
AB - Background: Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. Erlotinib plus an angiogenesis inhibitor (erlotinib+A) has demonstrated efficacy in controlling malignant pleural effusion (MPE) through reduction of vascular permeability; however, no clinical trials have directly compared its MPE control efficacy with that of osimertinib. This study aimed to compare the efficacy of osimertinib vs. erlotinib+A in controlling MPE in patients with EGFR-mutant NSCLC. Methods: This multicenter retrospective cohort study analyzed longitudinal medical records of patients with advanced or recurrent EGFR-mutant NSCLC presenting with MPE at treatment initiation who received osimertinib or erlotinib+A at 14 institutions in Japan between November 2009 and October 2023. Patients with squamous cell carcinoma were excluded. The primary endpoint was time to MPE recurrence [MPE-progression-free survival (PFS)]. Secondary endpoints included PFS, overall survival (OS), and adverse events (AEs) graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Multivariable Cox proportional hazards regression served as the primary analysis, with propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) utilized for sensitivity analyses. Results: Among 421 patients (median age, 73 years; 65% female; 66% never-smokers; 99% adenocarcinoma), 373 received osimertinib and 48 received erlotinib+A. In the multivariable Cox regression analysis, no significant differences were observed between the osimertinib and erlotinib+A groups in MPE-PFS [adjusted hazard ratio (HR): 0.79; 95% confidence interval (CI): 0.54–1.15; P=0.22], PFS (adjusted HR: 0.87; 95% CI: 0.60–1.25; P=0.45), or OS (adjusted HR: 0.95; 95% CI: 0.63–1.44; P=0.83). However, a significant interaction between the treatment regimen and EGFR mutation type was identified (P=0.004 for MPE-PFS). Subgroup analysis demonstrated that osimertinib was significantly superior to erlotinib+A in patients with EGFR exon 19 deletions (MPE-PFS: adjusted HR: 0.38; 95% CI: 0.21–0.67; P<0.001), whereas no difference was observed in those with L858R mutations. Grade ≥3 AEs were more frequent in the erlotinib+A group (38% vs. 21%, P=0.02), whereas osimertinib was associated with a higher incidence of all-grade interstitial pneumonia (21% vs. 6%, P=0.01). Conclusions: Osimertinib showed comparable efficacy to erlotinib+A in MPE control with a more favorable safety profile. Subgroup analysis suggested a particular benefit in patients harboring EGFR exon 19 deletions, highlighting the potential importance of mutation subtype-based treatment selection. Given the retrospective design and potential for residual confounding, prospective validation is warranted.
KW - Non-small cell lung cancer (NSCLC)
KW - angiogenesis inhibitor
KW - epidermal growth factor receptor (EGFR)
KW - osimertinib
KW - pleural effusion
UR - https://www.scopus.com/pages/publications/105048858768
UR - https://www.scopus.com/pages/publications/105048858768#tab=citedBy
U2 - 10.21037/tlcr-2026-0343
DO - 10.21037/tlcr-2026-0343
M3 - Article
AN - SCOPUS:105048858768
SN - 2218-6751
VL - 15
JO - Translational Lung Cancer Research
JF - Translational Lung Cancer Research
IS - 8
M1 - 228
ER -